Would definitely recommend
Disclosure of interest: Lino Braadt: nothing to disclose, Markus Naumann: nothing to disclose, Dennis Freuer: nothing to disclose, Christa Meisinger: nothing to disclose, Jakob Linseisen: nothing to disclose, Michael Ertl: nothing to disclose Scientific Communications: atherosclerosis and stroke 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.04 - STROKE COMPLICATIONS O - ESOC25-536 SAFETY AND EFFICACY OF DRUG-COATED BALLOON IN PATIENTS WITH SEVERE VERTEBRAL ARTERY ORIGIN STENOSIS (DCB-VAOS): A MULTICENTRE RANDOMISED TRIAL Liqun Jiao 1 , Yabing Wang 1 , Tao Wang 1,1 , Jichang Luo 1 , Rixuan Peng 1 , Changchun Jiang 2 , Haibo Wang 3 1 The Departments of Neurosurgery and Interventional Neuroradiology, Beijing, China, 2 Department of Neurology, Inner Mongolia Autonomous Region, China, 3 Peking University Clinical Research Institute, Beijing, China Background and Aims: Restenosis post endovascular treatment of vertebral artery origin stenosis (VAOS), with/without a bare-metal stent (BMS) and linked to recurrent stroke/death, is high compared to other vascular lesions
These are anecdotal, but the pattern is consistent with complaints filed against other 503A compounders operating at high volume during the GLP-1 demand surge of 2023 to 2025
One owner added BPC-157 to her dogs food after he had a partial tear in one of his knee ligaments
Normal (non-neoplastic) prostatic tissue (NNT)
Researchers concluded that resistance to the peptide is unlikely to arise from long-term treatment and greater weight loss may be shown over time
